Monkeypox virus isolation from longitudinal samples in 11 hospitalised patients.

Competing Interests: CFH received funding for this study from the Healthcare Infection Society (SRG/2022/03/002), via the UK Health Security Agency. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. JD, MGS, JKB, and ISARIC4C are supported by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool in partnership with the UK Heath Security Agency, in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907). The research was supported by The Pandemic Institute, formed of seven founding partners: The University of Liverpool, Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool City Council, Liverpool City Region Combined Authority, Liverpool University Hospital Foundation Trust, and Knowledge Quarter Liverpool. MGS is based at The University of Liverpool. The views expressed are those of the author(s) and not necessarily those of The Pandemic Institute. MGS has additionally received funding for this work from the UK Medical Research Council. MGS is an independent external and non-remunerated member of Pfizer's External Data Monitoring Committee for their mRNA vaccine programme(s); Chair of Infectious Disease Scientific Advisory Board for Integrum Scientific, Greensboro, NC, USA; and director and majority shareholder of MedEx Solutions. MGS is minority shareholder in Integrum Scientific, Greensboro, NC, USA. MGS has received gifts to their institution in the form of investigational medicinal product from Chiesi Farmaceutici. All other authors declare no competing interests. HC, CH, TR, JO, and KR accessed and verified the data in this study. Information on ethical approvals is provided in the appendix (p 6). The ISARIC4C investigators are listed in the appendix (pp 1–2).